China Plant Expected To Start Supplies In Second Half Of FY25: Cipla Q4 Press Conference | CNBC TV18

Points Friday to Friday, so let’s see. But you know Cipla is what we were discussing earlier that Q&A session was going on and we kind of sort of compress it together with what the key takeaways really are. So I just want to sort of play that out for you. Well, yes, you know Cipla actually what was a disappointment was also the US business this quarter which I mentioned $226 million is what they’ve reported. The Street was anticipating up to around 230, thirty million plus in terms of revenues on the upper end and hence that’s probably been a disappointment this time. The company did mention that the base level margins for the company or the base level sales for the US should be 215 to two $20 million. U.S. sales will be responsive to launches going forward and it should probably be higher than last quarter. Now margins, margins, they did decline. There were some amount of, you know, freight costs on account of the Red Sea which were higher this quarter, but they did see seasonality and that’s the reason why you’ve seen this year in your, you know, decline in terms of Q&Q decline in terms of margins, guidance remains at 24 to 25%. Now in terms of key approvals, a breaks on approval is dependent on the clearance of the Goa facility. They are closer to remediation of the Indore plan. They would be open to marketing Eli Lilly’s weight loss drug in India and they are working on a weight loss obesity drug in India as well as well. So that should probably be a future trigger, but in the near term I think it would be the margin improvement. the US sales are moving up. Which would probably be important to watch. OK. Thank you, Ekta, for that. Hema, We were just chatting with one of the analysts.